Eastern Cooperative Oncology Group

约翰斯·霍普金斯自1955年以来一直是ECOG的成员。我们的主要目标是为集团带来创新的临床研究方案和在约翰霍普金斯大学试点的实验室相关科学，以供进一步发展。此外，我们的教员还担任研究主席和实验室联合主席、疾病和医疗保健委员会主席等领导角色。 具体目标是：1)继续在以下以疾病为导向的委员会中发挥科学领导作用：乳房、胸科、头颈、泌尿生殖系统、脑瘤工作组、淋巴瘤、白血病；2)继续扩大我们对疾病和模式委员会的参与：胃肠、骨髓瘤、药理学和药物开发；将翻译研究相关、细胞生物学和分子生物学纳入疾病所有阶段的临床方案；4)继续扩大应计，并保持数据质量方面的优异表现。 这些目标将通过约翰霍普金斯大学西德尼·基梅尔综合癌症中心的使命来实现：为癌症研究提供多学科方法，从而改进预防、诊断和治疗手段。该中心在翻译研究方面取得了卓越的成就，授予了七项孢子赠款(子宫颈、淋巴瘤、G-L癌、前列腺癌、乳腺癌、肺癌、头颈部)。此外，新药的早期临床试验是根据NCI第一阶段合同进行的(自1982年以来)。早期治疗开发与第二阶段重点赠款允许开发新的第二阶段和第三阶段概念，癌症中心的教职员工通过适当的实验室科学相关研究将这些概念带给ECOG。中心设施的扩展允许开发新的临床项目，招聘新的教师，进一步促进委员会的参与和临床试验的收益。

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative science piloted at Johns Hopkins to the Group for further development. In conjunction with this, our faculty serve in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The specific aims are: 1) to continue to provide scientific leadership in the disease-oriented committees: Breast, Thoracic, Head and Neck, Genitourinary, Brain Tumor Working Group, Lymphoma, Leukemia; 2) to continue to expand our involvement in the disease and modality committees: Gastrointestinal, Myeloma, Pharmacology and Drug Development; to bring translational research correlates, cell biology and molecular biology into clinical protocols for all stages of disease; 4) to continue to expand accrual, and to maintain excellent performance in data quality. These goals will be accomplished through the mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: to provide a multidisciplinary approach to the study of cancer that will result in improved means for prevention, diagnosis, and treatment. The Center has achieved excellence in translational research with the awarding of seven SPORE grants (cervix, lymphoma, G-l cancer, prostate, breast, lung, head and neck). In addition, early clinical trials of new drugs are conducted under the NCI phase I contract (since 1982). The Early Therapeutics Development with Phase II Emphasis grants allow the development of novel phase II and phase III concepts which the Cancer Center faculty bring to ECOG with appropriate laboratory science correlative studies. The expansion of Center facilities allows the development of new clinical prograins, the recruitment of new faculty, furthering committee involvement and clinical trial accrual.